Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...